Founder and Chief Executive Officer (since 2024), Vivaldi Rare , a provider of pharma and biotech consulting services President and Chief Executive Officer (2018 - 2023 when it was acquired by Eli Lilly and Company), Sigilon Therapeutics, Inc. , a diabetes cell therapy company Executive Vice President and Chief Global Therapeutics Officer (2016 - 2018 when it was acquired by Sanofi), Bioverativ Inc. , a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders Executive Vice President and Chief Commercial Officer (2014 - 2016), Spark Therapeutics, Inc. , a gene therapy company Chief Executive Officer (2013 - 2014), Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of product candidates to treat patients suffering from central nervous system diseases Earlier in his career, held positions of increasing responsibility including leading rare disease business as President of both the rare disease business and the renal and endocrine group and served as Senior Vice President and General Manager of the Latin America Group, Genzyme Corporation Key Skills and Experience: CEO and Public Company Management, Corporate Governance, Finance, Accounting, and Capital Markets, Healthcare Industry, Risk Oversight/Compliance, and Strategy and M&A Experience obtained over his many years in leadership positions in the healthcare industry, where he gained extensive experience leading and managing commercial, marketing, and sales operations, managing patient access initiatives, and leading the successful approval of innovative medicines Dr. Vivaldi also brings Global Business and Human Capital Management Experience to the Board Other Current Public Company Boards: Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) (since 2022), Director and member of the Audit Committee and the Research and Development Committee Former Public Company Boards: Sigilon Therapeutics, Inc. (2018 - 2023 when it was acquired by Eli Lilly and Company), Director Minerva Neurosciences, Inc. (NASDAQ: NERV) (2013 - 2014), Director Former Private Company Boards: Spark Therapeutics, Inc. (2014), Director